# Therapeutic for Tissue Fibrosis

**OCR Number:** OCR 7100

**Description:**

**MKP-5 Allosteric modulation: anti-fibrotic therapeutics**

**About MKP-5 expression/indications**
- Liver, sk. muscle, lung, hematopoietic system and vasculature
- MKP-5 antagonism for multiple fibrotic indications
- MKP-5 is safely KO’d
- MKP-5 family & pathway well-characterized/TGFβ-1
- MKP-5 upregulated with chronic muscle damage/Ducahene muscular dystrophy (DMD)

**Available assays/in vivo models**
- In vitro: assays for efficient lead identification/selection
- In vivo DMD/MXD model: MDX/MKP-5 KO blocks progression of DMD

**About the hit/Structure-based design**
- OCR7100 is a µM allosteric modulator
- OCR7100 is selective for MKP-5 (vs. MKP-1 & MKP-3)
- OCR7100 has been co-crystallized with MKP-5

**Novelty/surprising result**
- New compositions of matter by design
- Mechanism of inhibition is allosteric, not active site

**OCR7100 IP Status:**
- Unpublished
- Provisional patent filed
- Both available under CDA

**Publications:**

**PI:** Anton Bennett

**Licensing Contact:** David Lewin
david.lewin@yale.edu